Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295772 | 1.00 | DGAT1 (0.35) | DGAT1MAPT | |
| SCHEMBL29854683 | 0.86 | DGAT1 (0.38) | DGAT1MAPT | |
| SCHEMBL2693867 | 0.86 | DGAT1 (0.38) | DGAT1MAPT | |
| SCHEMBL25239242 | 0.85 | DGAT1 (0.40) | DGAT1MAPT | |
| SCHEMBL30456780 | 0.85 | DGAT1 (0.40) | DGAT1MAPT | |
| SCHEMBL13521625 | 0.85 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL21678682 | 0.85 | DGAT1 (0.40) | DGAT1MAPT | |
| SCHEMBL15753342 | 0.85 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL2696013 | 0.84 | DGAT1 (0.35) | DGAT1MAPT | |
| SCHEMBL29869832 | 0.83 | DGAT1 (0.34) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-02-13 | — | — | US | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-111278840-B | Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer | 癌症研究科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3668882-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-111278840-A | Pyrrolo [2, 3-B ] pyridine compounds and their use for treating cancer | 癌症研究科技有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2019034890-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | DGAT1 4832/4885MAPT 2806/4885 |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, MAPT | DGAT1 3150/4885MAPT 3/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | DGAT1 3116/4885MAPT 5/4885 |
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | STK3, STK4, STK36 | DGAT1 4167/4885MAPT 915/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | DGAT1 3150/4885MAPT 3/4885 |
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | DGAT1 3881/4885MAPT 2120/4885 |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | DGAT1 4090/4885MAPT 3844/4885 |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | DGAT1 4742/4885MAPT 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.